Hepatitis of unknown aetiology in children – epidemiological overview of cases reported in Europe, 1 January to 16 June 2022Adriana Romaní Vidal, Christopher Williams, Aisling Vaughan et al.|Eurosurveillance|2022Cited by 29
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona CohortRoberta Gagliardini, Stefano Bonora, S De Benedittis et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 15
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohortAntonella d’Arminio Monforte, Carlo Torti, Alessandro Tavelli et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 9
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of viewAntonella Cingolani, Stefano Bonora, A Tavelli et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 2
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohortAlessandra Vergori, Antonella Castagna, Antonella d’Arminio Monforte et al.|Journal of Antimicrobial Chemotherapy|2025Cited by 2